ReviewCancers2026

PD-L1-Guided Chemo-Immunotherapy in Advanced Triple-Negative Breast Cancer: A Meta-Analysis of Survival Benefits and Toxicity Profiles.

Lingshan Nan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.